Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR | P00533 | 3/20 | 0.54 |
| ▸ | FLT3 | P36888 | 4/20 | 0.44 |
| ▸ | PDGFRB | P09619 | 6/20 | 0.40 |
| ▸ | KDR | P35968 | 6/20 | 0.40 |
| ▸ | FGFR1 | P11362 | 4/20 | 0.40 |
| ▸ | ZAP70 | P43403 | 1/20 | 0.40 |
| ▸ | CDK2 | P24941 | 2/20 | 0.39 |
| ▸ | PDGFRA | P16234 | 2/20 | 0.39 |
| ▸ | AURKB | Q96GD4 | 1/20 | 0.39 |
| ▸ | CSF1R | P07333 | 1/20 | 0.38 |
| ▸ | FLT1 | P17948 | 1/20 | 0.38 |
| ▸ | MET | P08581 | 3/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | CCNE1 | P24864 | 1/20 | 0.38 |
| ▸ | RECQL | P46063 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | PTK2B | Q14289 | 1/20 | 0.38 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.38 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6321459 | 0.94 | EGFR (0.53) | EGFRFLT3PDGFRBKDRFGFR1 | |
| SCHEMBL6321463 | 0.94 | EGFR (0.53) | EGFRFLT3PDGFRBKDRFGFR1 | |
| SCHEMBL6324032 | 0.90 | EGFR (0.51) | EGFRFLT3PDGFRBKDRFGFR1 | |
| SCHEMBL6324029 | 0.90 | EGFR (0.51) | EGFRFLT3PDGFRBKDRFGFR1 | |
| SCHEMBL6320593 | 0.89 | EGFR (0.49) | EGFRFLT3PDGFRBKDRFGFR1 | |
| SCHEMBL6320588 | 0.89 | EGFR (0.49) | EGFRFLT3PDGFRBKDRFGFR1 | |
| SCHEMBL6321174 | 0.87 | EGFR (0.53) | EGFRFLT3PDGFRBKDRFGFR1 | |
| SCHEMBL6321270 | 0.86 | EGFR (0.52) | EGFRFLT3PDGFRBKDRFGFR1 | |
| SCHEMBL6322658 | 0.86 | EGFR (0.47) | EGFRFLT3PDGFRBKDRFGFR1 | |
| SCHEMBL6321268 | 0.86 | EGFR (0.52) | EGFRFLT3PDGFRBKDRFGFR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6861418-B2 | 4-aryl substituted indolinones | SUGEN, INC. (US) | 2005-03-01 | — | — | US | disclosed |
| US-20040157909-A1 | 4-Aryl substituted indolinones | SUGEN, INC. | 2004-08-12 | — | — | US | disclosed |
| US-6677368-B2 | 4-aryl substituted indolinones | SUGEN, INC. | 2004-01-13 | — | — | US | disclosed |
| US-20030069297-A1 | 4-aryl substituted indolinones | SUGEN, INC. | 2003-04-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030069297-A1 | 4-aryl substituted indolinones | CDK5, CAMK4, TNK2 | EGFR 367/4885FLT3 596/4885PDGFRB 575/4885 |
| US-20040157909-A1 | 4-Aryl substituted indolinones | CDK5, CAMK4, TNK2 | EGFR 367/4885FLT3 596/4885PDGFRB 575/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.